Readystate Asset Management LP Takes $6.10 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Readystate Asset Management LP purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 179,518 shares of the biopharmaceutical company's stock, valued at approximately $6,102,000. Readystate Asset Management LP owned 0.27% of Celldex Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in CLDX. KBC Group NV boosted its holdings in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Celldex Therapeutics during the second quarter valued at approximately $76,000. Los Angeles Capital Management LLC lifted its holdings in Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 638 shares in the last quarter. Quest Partners LLC lifted its holdings in Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 6,879 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 1,504 shares in the last quarter.

Insider Activity

In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 3.80% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on CLDX. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a "neutral" rating and a $45.00 price target on the stock. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 26th. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, Citigroup started coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $70.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $62.25.

Celldex Therapeutics Price Performance

NASDAQ:CLDX traded down $0.46 during midday trading on Thursday, hitting $26.12. The company's stock had a trading volume of 205,961 shares, compared to its average volume of 879,677. The firm has a market cap of $1.73 billion, a P/E ratio of -10.34 and a beta of 1.57. Celldex Therapeutics, Inc. has a fifty-two week low of $22.93 and a fifty-two week high of $53.18. The firm's 50 day moving average is $28.07 and its 200-day moving average is $34.16.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.